SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-006566
Filing Date
2022-05-02
Accepted
2022-05-02 06:24:08
Documents
15
Period of Report
2022-05-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20220502x8k.htm   iXBRL 8-K 42152
2 EX-1.1 plx-20220502xex1d1.htm EX-1.1 21824
3 EX-5.1 plx-20220502xex5d1.htm EX-5.1 17432
4 GRAPHIC plx-20220502xex5d1002.jpg GRAPHIC 8208
  Complete submission text file 0001558370-22-006566.txt   222780

Data Files

Seq Description Document Type Size
5 EX-101.SCH plx-20220502.xsd EX-101.SCH 3261
6 EX-101.LAB plx-20220502_lab.xml EX-101.LAB 16022
7 EX-101.PRE plx-20220502_pre.xml EX-101.PRE 10767
9 EXTRACTED XBRL INSTANCE DOCUMENT plx-20220502x8k_htm.xml XML 4816
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 22879278
SIC: 2836 Biological Products, (No Diagnostic Substances)